Q1 2018 EPS Estimates for Illumina, Inc. (ILMN) Lifted by William Blair
Illumina, Inc. (NASDAQ:ILMN) – Research analysts at William Blair raised their Q1 2018 EPS estimates for shares of Illumina in a research note issued to investors on Monday. William Blair analyst A. Murphy now anticipates that the life sciences company will post earnings per share of $1.02 for the quarter, up from their prior estimate of $1.01. William Blair also issued estimates for Illumina’s Q2 2018 earnings at $1.04 EPS, Q4 2018 earnings at $1.19 EPS, FY2018 earnings at $4.44 EPS and FY2019 earnings at $5.03 EPS.
A number of other research firms also recently weighed in on ILMN. Leerink Swann reaffirmed an “outperform” rating and set a $225.00 price objective (up from $207.00) on shares of Illumina in a report on Tuesday, September 12th. Piper Jaffray Companies reiterated an “overweight” rating and set a $226.00 target price (up previously from $202.00) on shares of Illumina in a research report on Monday, October 9th. Citigroup Inc. upped their target price on shares of Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a research report on Wednesday, October 25th. Janney Montgomery Scott upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. Finally, Bank of America Corporation upped their price objective on shares of Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a research report on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company. Illumina currently has an average rating of “Hold” and an average target price of $200.88.
Illumina (NASDAQ ILMN) opened at $213.45 on Wednesday. Illumina has a 1-year low of $119.37 and a 1-year high of $214.50. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $30,960.00, a PE ratio of 61.60, a price-to-earnings-growth ratio of 3.48 and a beta of 0.74.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. Illumina’s revenue was up 17.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.97 earnings per share.
Several institutional investors and hedge funds have recently modified their holdings of the company. Moors & Cabot Inc. boosted its stake in shares of Illumina by 7.1% during the third quarter. Moors & Cabot Inc. now owns 7,500 shares of the life sciences company’s stock valued at $1,497,000 after purchasing an additional 500 shares during the period. IFM Investors Pty Ltd bought a new position in Illumina in the third quarter worth about $804,000. DF Dent & Co. Inc. raised its holdings in Illumina by 4.0% in the third quarter. DF Dent & Co. Inc. now owns 486,530 shares of the life sciences company’s stock worth $96,917,000 after purchasing an additional 18,741 shares in the last quarter. Neuberger Berman Group LLC raised its holdings in Illumina by 10.0% in the third quarter. Neuberger Berman Group LLC now owns 5,384 shares of the life sciences company’s stock worth $1,072,000 after purchasing an additional 491 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Illumina in the third quarter worth about $577,000. 90.76% of the stock is owned by hedge funds and other institutional investors.
In other Illumina news, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $205.71, for a total transaction of $29,827.95. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jay T. Flatley sold 22,540 shares of Illumina stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $195.21, for a total transaction of $4,400,033.40. Following the sale, the director now owns 539,176 shares in the company, valued at approximately $105,252,546.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 172,446 shares of company stock valued at $35,486,114. 0.89% of the stock is owned by company insiders.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.